论文部分内容阅读
目的 观察慢性乙型肝炎抗病毒治疗序贯疗法的临床效果。方法 拉米夫定组:拉米夫定100mg, 口服,每日1次,疗程1年。序贯治疗组:先单用拉米夫定治疗5个月,然后拉米夫定与干扰素α-2b联用1个月, 停用拉米夫定,继续用干扰素α-2b,5Mu,肌肉注射,隔日1次,疗程5个月。结果 治疗12个月研究组HBV- DNA阴转率为56.25%(18/32),ALT复常率为59.36%(19/32),与对照组比较无显著性差异(P>0.05),研究组 无一例检测出YMDD阳性,有显著性差异(P<0.01)。结论 序贯治疗可有效地减少YMDD变异发生的机会, 巩固抗病毒治疗的效果。
Objective To observe the clinical effect of sequential therapy of chronic hepatitis B antiviral therapy. Methods Lamivudine group: Lamivudine 100mg, orally, once daily, for 1 year. Sequential treatment group: first lamivudine treatment for 5 months, then lamivudine and interferon α-2b combined with 1 month, disable lamivudine, continue to use interferon α-2b, 5Mu , Intramuscular injection, every other day 1, course of treatment 5 months. Results The rate of HBV-DNA negative conversion in the study group was 56.25% (18/32) and the rate of ALT normalization was 59.36% (19/32) in the 12-month study. There was no significant difference between the two groups (P> 0.05) None of the cases detected YMDD positive, there was a significant difference (P <0.01). Conclusion Sequential treatment can effectively reduce the chance of YMDD mutation and consolidate the effect of antiviral therapy.